All News

2058 articles, sorted by publication time.

Drug Development · global

Locking Two Proteins Together: J&J’s Prostate Cancer Drug Shows Tumor Responses in 12 of 16 Patients in Early Trial

The oral investigational drug JNJ-6143 uses a RIPTAC mechanism to constrain a protein cancer cells need to survive, showing antitumor signals in patients who have received multiple treatments. But the 75% response rate comes from 16 patients; how long the effects last and whether the drug can extend life remain questions for further research.

Precision Medicine · global

Roche’s Two HER2 Tests Gain Expanded Approval to Support First-Line Ziihera Treatment for Gastroesophageal Cancer

Even among HER2-positive patients, protein expression and genetic test results can affect treatment eligibility. The FDA has expanded the approved uses of Roche’s companion diagnostics, providing corresponding pathology-based screening criteria for new treatments for gastric, gastroesophageal junction, and esophageal adenocarcinoma.

Cancer and New Drugs · global

A New Option After Chemotherapy and Immunotherapy: sac-TMT Extends Survival in Advanced Endometrial Cancer

In a 776-patient phase 3 trial, sac-TMT extended median overall survival from 12.1 months to 19 months, but grade 3 or higher treatment-related adverse events were also more frequent. The FDA has accepted the application for priority review. Translating efficacy into clinical treatment choices still requires consideration of toxicity and evidence across different patient populations.

Precision Medicine · uk

Testing drugs on virtual tumors first: symbolic AI retrospectively predicts breast cancer response, with 74% agreement across 31 cases

Researchers used patients’ genetic data to build tumor “digital twins,” reproducing existing treatment responses and identifying potential drug options for those with incomplete responses. However, the improvements predicted by computer simulations still require validation in prospective clinical studies.